What are the adverse reactions of Glyceryl Phenylbutyrate Oral Solution (Ravicti)?
Glycerol Phenylbutyrate Oral Liquid (Glycerol Phenylbutyrate Oral Liquid) is a drug used to treat urea cycle disorders. Although it has achieved significant clinical efficacy, its use is also accompanied by some adverse reactions. In clinical studies, patients commonly report a range of common symptoms, including diarrhea, headache, bloating, abdominal pain and vomiting. Diarrhea is one of the most common side effects and may cause patients to have frequent bowel movements and affect their fluid and electrolyte balance. At the same time, the occurrence of nausea and vomiting will not only cause physical discomfort to the patient, but may also cause a loss of appetite, thereby affecting the patient's nutritional intake.

In addition to the digestive discomfort mentioned above, patients may also experience more common reactions such as fatigue, dizziness, and indigestion. The severity of these symptoms varies among patients and may be affected by individual differences and medication dosage. For some patients, abdominal discomfort is also a concern, which not only affects their daily life, but may also further increase drug dependence and the patient's psychological burden.
It is worth noting that some new adverse events have emerged after the drug was launched. These events include abnormal body odor, and patients may notice that their skin, hair, and urine smell odorous, a condition that may trigger social anxiety or feelings of low self-esteem in some people. In addition, some patients report dysgeusia and a burning sensation in the mouth, which, although relatively rare, can affect patients' eating experience and reduce their enjoyment of food.
In summary, although glyceryl phenylbutyrate oral solution is excellent in controlling urea cycle disorders, its potential adverse effects cannot be ignored. Patients should pay close attention to their physical reactions during use and promptly report discomfort symptoms to medical staff so that necessary adjustments and management can be made.
Reference materials:https://www.ravicti.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)